Preview

Rational Pharmacotherapy in Cardiology

Advanced search

«MEMORIES OF FUTURE»: CHANGE IN VERAPAMIL SIGNIFICANCE IN THE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION

https://doi.org/10.20996/1819-6446-2014-10-6-672-678

Full Text:

Abstract

The significance of verapamil in the treatment of patients with ischemic heart disease (IHD) and hypertension (HT) is considered. Data on the limited role of beta-blockers in the improvement of patient’s status in stable IHD, data about negative effect of heart rate (HR) reduction on the central aortic pressure, as well as the relationship between HR and risk of complications in the INVEST trial are presented. Verapamil therapy in patients with HT and IHD without heart failure/systolic dysfunction and/or recent myocardial infarction may have advantages due to achievement of the sufficient antiischemic effect with less HR reduction.

About the Author

S. R. Gilyarevskiy
Russian Medical Academy of Postgraduate Education
Russian Federation
Barrikadnaya ul. 2/1, Moscow, 123995 Russia


References

1. Fox K., Borer J.S., Camm A.J., et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-30.

2. Fox K.M., Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 2011;8: 369-79.

3. Diaz A., Bourassa M.G., Guertin M.C., Tardif J.C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-74.

4. Kannel W.B., Kannel C., Paffenbarger R.S.J.R. Jr, Cupples L.A. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-94.

5. Böhm M., Swedberg K., Komajda M., et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomized placebo-controlled trial. Lancet 2010;376:886-94.

6. Fox K., Ford I., Steg P.G., et al. Ivabradine in stable coronary artery disease with outclinical heart failure. N Engl J Med 2014;371:1091-9.

7. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001;357:1385-1390.

8. Chen J., Radford M.J., Wang Y., et al. Are β-blockers effective in elderly patients who undergo coronary revascularization after acute myocardial infarction? Arch Intern Med 2000;160:947-52.

9. Kramer J.M., Hammill B., Anstrom K.J., et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006;152:454, e1-e8.

10. Topouchian J., Asmar R., Sayegh F., et al. Changesin Arterial Structure and Function Under Trandolapril-Verapamil Combination in Hypertension. Stroke 1999;30:1056-64.

11. Mitchell G.F., Dunlap M.E., Warnica W., et al. Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness. The Prevention of Events With Angiotensin-Converting Enzyme Inhibition Hemodynamic Substudy. Hypertension 2007;49:1271-7.

12. Bangalore S., Sawhney S., Messerli F.H. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008;52:1482-9.

13. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M., et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. TheInternationalVerapamil-TrandolaprilStudy (INVEST): a randomizedcontrolledtrial. JAMA 2003;290:2805-2816.

14. Kolloch R., Legler U.F., Champion A., et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the International VErapamil-SR/trandolapril Study (INVEST). Eur Heart J 2008;29:1327-34.

15. Cook S., Togni M., Schaub M.C., et al. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387-293.

16. National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update. NICE Clinical Guideline. London: Royal College of Physicians; 2006.

17. Palatini P., Benetos A., Julius S. Impact of increased heart rate on clinical outcomes in hypertension: implications for antihypertensive drug therapy. Drugs 2006;66:133-144.

18. Mancia G., DeBacker G., Dominiczak A., et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007;25:1751-1162.

19. Rosendorff C., Black H.R., Cannon C.P., etal.Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Researchand the Councilson Clinical Cardiology and Epidemiology and Prevention. Circulation 2007;115:2761-88.

20. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding end roflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005;366:895-906.

21. Poulter N.R., J.E. Dobson, Sever P.S., et al. Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009;54:1154-61.


For citation:


Gilyarevskiy S.R. «MEMORIES OF FUTURE»: CHANGE IN VERAPAMIL SIGNIFICANCE IN THE TREATMENT OF PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. Rational Pharmacotherapy in Cardiology. 2014;10(6):672-678. (In Russ.) https://doi.org/10.20996/1819-6446-2014-10-6-672-678

Views: 392


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)